Newsletter
Jan 14, 2026
•
1 min read
GLP-1 suicide language gets cut, Travere slips 3 months, and Novartis keeps buying RLT shots on goal.
Jan 13, 2026
AbbVie grabs ex-China rights to a PD-1 x VEGF, argenx gets Priority Review, and Merck/Daiichi’s hold lifts.
Jan 12, 2026
Sanofi gets an EU nod in T1D, Teva/Royalty fund vitiligo, and Eikon tests the IPO window.
Jan 9, 2026
Merck circles Revolution, Aktis prints the first biotech IPO of 2026, big private rounds land, and 340B stays blocked.
Jan 8, 2026
A $1.2B NLRP3 takeout, a $130M raise, and a $205M-plus-royalties APAC license.
Jan 7, 2026
Relation+Deerfield spin out new companies, Ziihera posts late-stage results, and J&J tees up lupus Phase 3.
Jan 6, 2026
CDC narrows the childhood schedule, FDA explains a Sanofi MS CRL, and HHS pushes AZN’s case away.
Jan 5, 2026
Servier taps Insilico’s AI platform, Novo prices the Wegovy pill, and Sanofi’s Tzield gets priority review.
Dec 30, 2025
Ultragenyx/Mereo stumble in rare bone disease, a small raise prints, and Denali lands an NEJM publication.
Dec 29, 2025
CMS tees up a new GLP-1 payment model, Biohaven eats a Phase 2 miss, and J&J trims a $1.25B deal.
Dec 24, 2025
Dynavax lands in Sanofi’s cart, oral Wegovy gets the green light, and Medicare pricing carve-outs loom.
Dec 23, 2025
Oral GLP-1 gets an FDA greenlight, CMS floats new pricing demos, and Shionogi drops $2.5B on ALS.
Dec 22, 2025
Cytokinetics lands a first approval, BioMarin goes big, and drug pricing deals widen their footprint.
Dec 19, 2025
Regeneron sets an Eylea-biosimilar launch window; Ipsen’s FOP readout flops; policy hawks eye China.
Dec 18, 2025
BioNTech closes CureVac, schizophrenia cash pours in, and FDA clears a twice-yearly asthma biologic.
Dec 17, 2025
GSK gets an asthma win, Alvotech taps convertibles, and Sanofi lands EU orphan status in emphysema.
Dec 16, 2025
Big Pharma wants faster approvals, Sanofi juggles setbacks and deals, and CAR-T pushes deeper into autoimmunity.
Dec 15, 2025
FDA cleared a new arrhythmia nasal spray as gene therapy safety questions resurfaced.
Dec 12, 2025
FDA turmoil, jumbo Kymera/Dyne raises, and a biomarker win in Parkinson’s as XBI keeps grinding higher.
Dec 11, 2025
Biotech rips on risk-on tape as Immunovant prices $550M, Sanofi wins in China, and obesity, AI, and antibiotics crowd the docket.
Dec 10, 2025
Wednesday’s biotech tape split from the broader market as ASH data, chunky financings, and fresh FDA safety probes hit the sector.
Dec 9, 2025
Terns challenges Novartis, FDA tightens CAR-T bar, Mirum buys Bluejay.
Dec 8, 2025
ASH blood disorder data, hep B birth-dose reversal, Freenome’s $330M SPAC, and more.
Dec 5, 2025
FDA leadership churn and vaccine politics, ACIP punts again, plus fresh CNS, oncology and kidney data.
Dec 4, 2025
Former FDA chiefs revolt, Capricor redeems its DMD play, user fees target ex-US Phase 1—and XBI jumps.
